The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

AI fundraises, tech partnerships and M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Find insight on Hims & Hers, U.K. pharmaceutical stocks, Novo Nordisk, AstraZeneca and more in the latest Market Talks ...

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. The day's gain was powered by the telehealth company's ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

U.S. stock futures slipped on Monday night as the market awaited clarity from President Donald Trump regarding his tariff ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a look at where Hims & Hers Health Inc (NYSE:HIMS) stands against other ...

The starter dose for Zepbound is $349. But "$500 is still a lot of money for a lot of people," Dr. Craig Primack, senior vice president for weight loss at Hims & Hers, said in an interview.

Hims & Hers is a newfangled telehealth company that ... Then, on 5/20/24, HIMS metaphorically pushed harder on the launch button. It announced it would make GLP-1 injections available to its ...